Stanley J. Hollenbach

2.6k total citations · 1 hit paper
40 papers, 2.0k citations indexed

About

Stanley J. Hollenbach is a scholar working on Hematology, Cardiology and Cardiovascular Medicine and Internal Medicine. According to data from OpenAlex, Stanley J. Hollenbach has authored 40 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 18 papers in Cardiology and Cardiovascular Medicine and 9 papers in Internal Medicine. Recurrent topics in Stanley J. Hollenbach's work include Atrial Fibrillation Management and Outcomes (14 papers), Blood Coagulation and Thrombosis Mechanisms (12 papers) and Venous Thromboembolism Diagnosis and Management (9 papers). Stanley J. Hollenbach is often cited by papers focused on Atrial Fibrillation Management and Outcomes (14 papers), Blood Coagulation and Thrombosis Mechanisms (12 papers) and Venous Thromboembolism Diagnosis and Management (9 papers). Stanley J. Hollenbach collaborates with scholars based in United States and Canada. Stanley J. Hollenbach's co-authors include Uma Sinha, Neill A. Giese, Nathalie A. Lokker, Carol M. Sullivan, Francis DeGuzman, Athiwat Hutchaleelaha, Genmin Lu, Mayuko Inagaki, Mark A. Israel and Pamela B. Conley and has published in prestigious journals such as Circulation, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Stanley J. Hollenbach

39 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

2013 533 citations Genmin Lu, Francis DeGuzman et al. Nature Medicine profile →

Peers

Countries citing papers authored by Stanley J. Hollenbach

Since Specialization

Citations

This map shows the geographic impact of Stanley J. Hollenbach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley J. Hollenbach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley J. Hollenbach more than expected).

Fields of papers citing papers by Stanley J. Hollenbach

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley J. Hollenbach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley J. Hollenbach. The network helps show where Stanley J. Hollenbach may publish in the future.

Co-authorship network of co-authors of Stanley J. Hollenbach

This figure shows the co-authorship network connecting the top 25 collaborators of Stanley J. Hollenbach. A scholar is included among the top collaborators of Stanley J. Hollenbach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanley J. Hollenbach. Stanley J. Hollenbach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model 2018 ·PLoS ONE ·Genmin Lu, (unknown), Janet M. Leeds, Francis DeGuzman, (unknown), (unknown), J Malinowski, Stanley J. Hollenbach, John T. Curnutte, Pamela B. Conley	30
2	Preclinical safety and efficacy of andexanet alfa in animal models 2017 ·Journal of Thrombosis and Haemostasis ·Genmin Lu, Stanley J. Hollenbach, Dale C. Baker, (unknown), Athiwat Hutchaleelaha, J T Curnutte, Pamela B. Conley	31
3	The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Greg Coffey, (unknown), Francis DeGuzman, Yvonne Pak, Mayuko Inagaki, Dale C. Baker, Stanley J. Hollenbach, Anjali Pandey, Uma Sinha	73
4	ABSENCE OF QTC PROLONGATION WITH BETRIXABAN: A RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND POSITIVE-CONTROLLED THOROUGH ECG STUDY 2013 ·Journal of the American College of Cardiology ·Uma Sinha, Joel Morganroth, Daniel D. Gretler, Stanley J. Hollenbach, Joseph L. Lambing	1
5	A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa breakdown → 2013 ·Nature Medicine ·Genmin Lu, Francis DeGuzman, Stanley J. Hollenbach, Mark J. Karbarz, Keith Abe, (unknown), Peng Luan, Athiwat Hutchaleelaha, Mayuko Inagaki, Pamela B. Conley, David R. Phillips, Uma Sinha	533
6	The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia 2012 ·Journal of Pharmacology and Experimental Therapeutics ·Stephen E. Spurgeon, Greg Coffey, Luke B. Fletcher, Russell T. Burke, Jeffrey Tyner, Brian Druker, (unknown), Francis DeGuzman, Yvonne Pak, Dale C. Baker, Anjali Pandey, Stanley J. Hollenbach, Uma Sinha, Marc Loriaux	40
7	PRT062070: A Dual Syk/JAK Inhibitor with Potent Immune Regulatory Capacity in Rodent Models of Inflammation and Cancer. 2012 ·Blood ·Greg Coffey, Francis DeGuzman, (unknown), Lynn Kamen, Dale C. Baker, Stanley J. Hollenbach, Anjali Pandey, Uma Sinha	4
8	Absence of QTc prolongation with betrixaban: a randomized, double-blind, placebo- and positive-controlled thorough ECG study 2012 ·Expert Opinion on Pharmacotherapy ·Joel Morganroth, Daniel D. Gretler, Stanley J. Hollenbach, Joseph L. Lambing, Uma Sinha	12
9	Thienopyridines, but Not Elinogrel, Result in Off-Target Effects at the Vessel Wall That Contribute to Bleeding 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Patrick André, Francis DeGuzman, Helena Haberstock-Debic, (unknown), Yvonne Pak, Mayuko Inagaki, Anjali Pandey, Stanley J. Hollenbach, David R. Phillips, Pamela B. Conley	21
10	Specific Inhibition of Spleen Tyrosine Kinase Suppresses Leukocyte Immune Function and Inflammation in Animal Models of Rheumatoid Arthritis 2011 ·Journal of Pharmacology and Experimental Therapeutics ·Greg Coffey, Francis DeGuzman, Mayuko Inagaki, Yvonne Pak, Suzanne M. Delaney, (unknown), (unknown), Zhaozhong J. Jia, Anjali Pandey, Dale C. Baker, Stanley J. Hollenbach, David R. Phillips, Uma Sinha	91
11	Abstract 12420: Reversal of Low Molecular Weight Heparin and Fondaparinux by a Recombinant Antidote (r-Antidote, PRT064445) 2010 ·Circulation ·Genmin Lu, Francis DeGuzman, Stanley J. Hollenbach, Peng Luan, Keith Abe, (unknown), Pamela B. Conley, David R. Phillips, Uma Sinha	8
12	N,N-Dialkylated 4-(4-arylsulfonylpiperazine-1-carbonyl)-benzamidines and 4-((4-arylsulfonyl)-2-oxo-piperazin-1-ylmethyl)-benzamidines as potent factor Xa inhibitors 2004 ·Bioorganic & Medicinal Chemistry Letters ·Zhaozhong J. Jia, Ting Su, (unknown), Yanhong Wu, Erick A. Goldman, Wenhao Li, Penglie Zhang, Lane A. Clizbe, Yonghong Song, (unknown), Wenrong Huang, John Woolfrey, Uma Sinha, Ann Arfsten, Athiwat Hutchaleelaha, Stanley J. Hollenbach, Joseph L. Lambing, Robert M. Scarborough, Bing‐Yan Zhu	12
13	Short-term intravenous eptifibatide infusion combined with reduced dose recombinant tissue plasminogen activator inhibits platelet recruitment at sites of coronary artery injury 2004 ·Journal of the American College of Cardiology ·(unknown), Aloke V. Finn, Robert C. Leinbach, Stanley J. Hollenbach, H. Thomas Aretz, Renu Virmani, Herman K. Gold	6
14	Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity 2004 ·Bioorganic & Medicinal Chemistry Letters ·Penglie Zhang, Liang Bao, (unknown), Zhaozhong J. Jia, John Woolfrey, Ann Arfsten, Susan Edwards, Uma Sinha, Athiwat Hutchaleelaha, Joseph L. Lambing, Stanley J. Hollenbach, Robert M. Scarborough, Bing‐Yan Zhu	19
15	Identification of 4-piperazin-1-yl-quinazoline template based aryl and benzyl thioureas as potent, selective, and orally bioavailable inhibitors of platelet-derived growth factor (PDGF) receptor 2004 ·Bioorganic & Medicinal Chemistry Letters ·Julie A. Heath, Mukund M. Mehrotra, (unknown), Jin‐Chen Yu, Athiwat Hutchaleelaha, Stanley J. Hollenbach, Neill A. Giese, Robert M. Scarborough, Anjali Pandey	12
16	Design, synthesis and structure–Activity relationships of benzoxazinone-Based factor Xa inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Wenrong Huang, Penglie Zhang, (unknown), Lingyan Wang, John Woolfrey, Yonghong Song, Zhaozhong J. Jia, Lane A. Clizbe, Ting Su, (unknown), Brian Huang, Paul Wong, Uma Sinha, Gary Park, (unknown), J Malinowski, Stanley J. Hollenbach, Robert M. Scarborough, Bing‐Yan Zhu	18
17	Design, synthesis, and structure–Activity relationships of unsubstituted piperazinone-Based transition state factor Xa inhibitors 2003 ·Bioorganic & Medicinal Chemistry Letters ·Wenrong Huang, (unknown), Hua Yang, Ting Su, (unknown), Paul Wong, Ann Arfsten, Susan Edwards, Uma Sinha, Stanley J. Hollenbach, Robert M. Scarborough, Bing‐Yan Zhu	13
18	CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML) 2002 ·Cancer Cell ·Louise Kelly, Jin‐Chen Yu, Christina Boulton, Mutiah Apatira, Jason Li, Carol M. Sullivan, Ifor R. Williams, (unknown), David P. Curley, Nicole Duclos, Donna Neuberg, Robert M. Scarborough, Anjali Pandey, Stanley J. Hollenbach, Keith Abe, Nathalie A. Lokker, D. Gary Gilliland, Neill A. Giese	240
19	Efficacy of the Novel Selective Platelet-Derived Growth Factor Receptor Antagonist CT52923 on Cellular Proliferation, Migration, and Suppression of Neointima following Vascular Injury 2001 ·Journal of Pharmacology and Experimental Therapeutics ·Jin‐Chen Yu, Nathalie A. Lokker, Stanley J. Hollenbach, Mutiah Apatira, Jason Li, (unknown), David M. Sedlock, Shoji Oda, Yuji Nomoto, Kenji Matsuno, (unknown), (unknown), Neill A. Giese	34
20	Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis 2000 ·European Journal of Pharmacology ·Uma Sinha, (unknown), J Malinowski, Bing Zhu, Robert M. Scarborough, Charles K. Marlowe, Paul Wong, Pei Lin, Stanley J. Hollenbach	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact